SLM6

• CAT Number: I036380
• CAS Number: 22242-91-7
• Molecular Formula: C12H17N7O4
• Molecular Weight: 323.31
• Purity: 98%
• Synonyms: SLM6; SLM-6; SLM 6; Sangivamycin-Like Molecule 6; NSC-107517; NSC 107517; NSC107517
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: N',4-diamino-7-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carboximidamide
• InChI: InChI=1S/C12H17N7O4/c13-9(18-15)4-1-19(11-6(4)10(14)16-3-17-11)12-8(22)7(21)5(2-20)23-12/h1,3,5,7-8,12,20-22H,2,15H2,(H2,13,18)(H2,14,16,17)
• InChIKey: WAMOLHIDNBDQSK-UHFFFAOYSA-N
• SMILES: C1=C(C2=C(N=CN=C2N1C3C(C(C(O3)CO)O)O)N)/C(=N/N)/N

SLM6（Cat No.:I036380）is an experimental small molecule being investigated for its potential therapeutic applications, particularly in the field of oncology. It works by targeting specific molecular pathways involved in cancer cell survival, proliferation, or resistance to treatment. By modulating these pathways, SLM6 aims to enhance the effectiveness of existing cancer therapies or overcome resistance to conventional treatments. Currently, SLM6 is undergoing preclinical or early clinical trials to assess its safety, efficacy, and pharmacokinetic properties. Further research is needed to determine its clinical potential, optimal dosing, and any associated side effects.